Deerfield Management Company, L.P. / CN2
Deerfield Management Company, L.P.’s Catalyst Pharmaceuticals Inc Position
Does Deerfield Management Company, L.P. own Catalyst Pharmaceuticals Inc (CN2)? Yes — 3.94M shares worth $98M (+1.15% of its 13F portfolio) as of Q1 2026, down from 4.91M shares the prior filed quarter.
Position Value
$98M
Q1 2026
Shares
3.94M
% of Portfolio
+1.15%
Quarters Held
15
currently held
Position History CN2
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 3.94M | $98M | +1.15% |
| Q4 2025 | 4.91M | $115M | +1.46% |
| Q3 2025 | 4.97M | $98M | +1.50% |
| Q2 2025 | 2.88M | $62M | +1.13% |
| Q1 2025 | 3.42M | $83M | +1.64% |
| Q4 2024 | 3.13M | $65M | +1.24% |
| Q3 2024 | 6.23M | $124M | +1.85% |
| Q2 2024 | 9.13M | $141M | +2.35% |
| Q1 2024 | 9.13M | $146M | +2.53% |
| Q4 2023 | 8.89M | $149M | +2.76% |
| Q3 2023 | 8.19M | $96M | +2.11% |
| Q2 2023 | 8.19M | $110M | +2.35% |
| Q1 2023 | 10.36M | $172M | +3.83% |
| Q4 2022 | 5.88M | $109M | +2.27% |
| Q3 2022 | 4.90M | $63M | +1.25% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Deerfield Management Company, L.P.’s full portfolio or all institutional holders of CN2.